$380 Million is the total value of INTERWEST VENTURE MANAGEMENT CO's 12 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 16.7% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
PMVP | Sell | PMV PHARMACEUTICALS INC | $179,905,000 | -54.8% | 5,469,911 | -15.5% | 47.32% | -4.8% |
AI | Sell | C3.AI | $91,402,000 | -62.0% | 1,386,774 | -20.0% | 24.04% | -20.0% |
REAL | Sell | THE REALREAL | $53,273,000 | -29.3% | 2,354,080 | -38.9% | 14.01% | +49.0% |
GKOS | Sell | GLAUKOS CORP | $29,071,000 | -40.2% | 346,364 | -46.4% | 7.65% | +25.9% |
STIM | Sell | NEURONETICS INC | $6,150,000 | -44.3% | 497,158 | -50.0% | 1.62% | +17.2% |
KALV | Exit | KALVISTA PHARMACEUTICALS INC | $0 | – | -388,766 | -100.0% | -0.92% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-04-15
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
GLAUKOS CORP | 28 | Q3 2023 | 33.0% |
EIGER BIOPHARMACEUTICALS INC | 24 | Q3 2022 | 17.7% |
APPLIED GENETIC TECHNOL CORP | 24 | Q3 2022 | 6.7% |
XENON PHARMACEUTICALS INC | 20 | Q3 2021 | 0.6% |
CIDARA THERAPEUTICS INC | 19 | Q2 2021 | 4.5% |
THE REALREAL | 18 | Q3 2023 | 62.6% |
KALVISTA PHARMACEUTICALS INC | 17 | Q4 2020 | 10.8% |
DARE BIOSCIENCE INC | 16 | Q3 2023 | 0.3% |
MACROGENICS INC | 14 | Q1 2020 | 19.2% |
PMV PHARMACEUTICALS INC | 13 | Q3 2023 | 67.5% |
View INTERWEST VENTURE MANAGEMENT CO's complete holdings history.
Latest filings
Type | Filed |
---|---|
144 | 2024-02-27 |
13F-HR | 2023-10-20 |
13F-HR | 2023-07-21 |
13F-HR | 2023-04-27 |
13F-HR | 2023-01-31 |
13F-HR | 2022-10-25 |
13F-HR | 2022-08-02 |
13F-HR | 2022-04-13 |
13F-HR | 2022-01-25 |
13F-HR | 2021-10-19 |
View INTERWEST VENTURE MANAGEMENT CO's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.